Lung Cancer News and Research

Latest Lung Cancer News and Research

Canon, MEDIAN to demonstrate LMS clinical application portfolio at ITEM

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials and clinical routine, announced today it will demonstrate its Lesion Management Solutions -LMS- clinical application portfolio together with Canon at ITEM, April 13-15, 2012 in Yokohama, Japan.

10 Apr 2012

Low-dose spiral CT cost-effective in reducing lung cancer deaths

Lung cancer is the most lethal cancer in the United States. According to the National Cancer Institute, lung cancer causes more than 150,000 deaths annually and has a survival rate of 16 percent. More Americans die of lung cancer each year than of cervical, breast, colon and prostate cancers combined.

10 Apr 2012

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

9 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that patient access to premium-priced targeted cancer treatments in Brazil and Mexico is improving, creating an opportunity for developers and marketers of epidermal growth factor receptor (EGFR) inhibitors.

5 Apr 2012

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

5 Apr 2012

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine.

5 Apr 2012

Study assesses link between antifolate medications, KRAS mutations and amplification

Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

5 Apr 2012

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.

5 Apr 2012

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

4 Apr 2012

IOM releases new report on public health dimensions of epilepsies

The Institute of Medicine (IOM) on March 30th released its new report on the public health dimensions of the epilepsies, the first authoritative independent appraisal of epilepsy and its management in the United States.

3 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

New drive to prevent youngsters from inhaling second-hand smoke at home

There has a rise in the number of smokers despite the fewer public places at which to light up and one of the world's highest cigarette prices. Sales have hit a four-year high in 2009: 2.44 billion cigarettes, or 6.7 million a day. This was a 12-per-cent rise over 2008's figure of 2.17 billion sold; in 2005, it was 2.09 billion.

1 Apr 2012

CT scans more effective than traditional lung cancer detection methods

A new study led by researchers at Mount Sinai School of Medicine indicates that CT scans are more effective than traditional lung cancer detection methods at identifying aggressive lung cancers in their most treatable stages.

31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.

31 Mar 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Lung Cancer News and Research

Latest Lung Cancer News and Research

Canon, MEDIAN to demonstrate LMS clinical application portfolio at ITEM

Low-dose spiral CT cost-effective in reducing lung cancer deaths

MD Anderson initiates Phase 1/2 entinostat-lapatinib ditosylate combination study in metastatic breast cancer

Towards a drug to control cystic fibrosis

Opportunity for developers and marketers of EGFR inhibitors in Brazil and Mexico

HSP27 protein can indicate lung damage during early stages of COPD

Belagenpumatucel-L improves survival for patients with stage 3B/4 NSCLC

Study assesses link between antifolate medications, KRAS mutations and amplification

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Combination treatment shows promise against NSCLC patients ineligible for bevacizumab

IOM releases new report on public health dimensions of epilepsies

Lilly announces results of three preclinical studies that focus on c-MET receptor

New data demonstrates anti-cancer activities of Oncoprex

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Clinical data for cabozantinib to be presented at ASCO annual meeting

New drive to prevent youngsters from inhaling second-hand smoke at home

CT scans more effective than traditional lung cancer detection methods

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

Cambridge Heart fourth quarter total revenue decreases to $557,000

The ultimate guide to lung research tools and protocols eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in